Discontinued — last reported Q2 '18
Amgen Deferred Tax Assets decreased by 6.3% to $1.37B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 15.5%, from $1.62B to $1.37B. Over 3 years (FY 2022 to FY 2025), Deferred Tax Assets shows an upward trend with a 398.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests potential future tax savings, while a decrease may indicate the utilization of these assets or valuation allowances.
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between acc...
Standard accounting item for large corporations with complex tax structures and international operations.
deferred_tax_assets| Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.00M | $2.35B | $1.86B | $1.78B | $1.71B | $1.62B | $1.51B | $1.39B | $1.46B | $1.37B |
| QoQ Change | — | >999% | -20.9% | -4.4% | -3.9% | -5.6% | -6.6% | -8.2% | +5.2% | -6.3% |
| YoY Change | — | >999% | — | — | — | -31.4% | -18.9% | -22.1% | -14.8% | -15.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.